APA (7th ed.) Citation

Gérard, L., Michot, J., Burcheri, S., Fieschi, C., Longuet, P., Delcey, V., . . . Galicier, L. (2012). Rituximab decreases the risk of lymphoma in patients with HTV-associated multicentric Castleman disease. Blood, 119(10), 2228. https://doi.org/10.1182/blood-2011-08-376012

Chicago Style (17th ed.) Citation

Gérard, Laurence, et al. "Rituximab Decreases the Risk of Lymphoma in Patients with HTV-associated Multicentric Castleman Disease." Blood 119, no. 10 (2012): 2228. https://doi.org/10.1182/blood-2011-08-376012.

MLA (9th ed.) Citation

Gérard, Laurence, et al. "Rituximab Decreases the Risk of Lymphoma in Patients with HTV-associated Multicentric Castleman Disease." Blood, vol. 119, no. 10, 2012, p. 2228, https://doi.org/10.1182/blood-2011-08-376012.